Argenx NV, of Breda, the Netherlands, said it started a phase II proof-of-concept trial testing ARGX-113 in pemphigus vulgaris (PV) patients. The open-label, noncontrolled trial will enroll up to 12 patients with mild to moderate PV who are either newly diagnosed or relapsing.